Cargando…

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

Detalles Bibliográficos
Autores principales:	Felten, Renaud, Gallais, Floriane, Schleiss, Cédric, Chatelus, Emmanuel, Javier, Rose-Marie, Pijnenburg, Luc, Sordet, Christelle, Sibilia, Jean, Arnaud, Laurent, Fafi-Kremer, Samira, Gottenberg, Jacques-Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575482/ https://www.ncbi.nlm.nih.gov/pubmed/34778844 http://dx.doi.org/10.1016/S2665-9913(21)00351-9

Ejemplares similares

Évolution de l’immunité cellulaire et humorale anti-SARS-CoV-2 après 3 doses de vaccins chez des patients traités par rituximab
por: Felten, R., et al.
Publicado: (2021)

Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases
por: Felten, Renaud, et al.
Publicado: (2021)

Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study
por: Scherlinger, Marc, et al.
Publicado: (2021)

Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection
por: Scherlinger, Marc, et al.
Publicado: (2021)

Effet de la vaccination anti-SARS-CoV-2 sur les symptômes prolongés post-Covid : résultat de l’enquête nationale VAXILONG
por: Scherlinger, M., et al.
Publicado: (2021)

Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France
por: Felten, Renaud, et al.
Publicado: (2021)

Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides
por: Felten, Renaud, et al.
Publicado: (2022)

Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
por: Gallais, Floriane, et al.
Publicado: (2022)

Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors
por: Solis, Morgane, et al.
Publicado: (2020)

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
por: Gallais, Floriane, et al.
Publicado: (2021)

Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination
por: Martinot, Martin, et al.
Publicado: (2021)

Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients
por: Gallais, Floriane, et al.
Publicado: (2022)

How and why are rheumatologists relevant to COVID-19?
por: Felten, Renaud, et al.
Publicado: (2020)

Comment et pourquoi les rhumatologues sont importants face à la crise du COVID-19 ?()
por: Felten, Renaud, et al.
Publicado: (2020)

Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage
por: Blaess, Julien, et al.
Publicado: (2020)

Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients
por: Danion, François, et al.
Publicado: (2017)

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
por: Felten, Renaud, et al.
Publicado: (2021)

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren’s syndrome
por: Kawka, Lou, et al.
Publicado: (2023)

Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry
por: Seror, Raphaèle, et al.
Publicado: (2022)

Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay
por: Drouot, Laurent, et al.
Publicado: (2020)

Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the Pandemic
por: Scherlinger, Marc, et al.
Publicado: (2022)

Navigating use of rituximab during the COVID-19 pandemic
por: Elahee, Mehreen, et al.
Publicado: (2023)

What does endemic COVID-19 mean for the future of rituximab?
por: Liew, David F L, et al.
Publicado: (2022)

Coordination régionale et suivi prospectif du traitement prophylactique et curatif de 301 patients traités par anticorps monoclonaux anti-SARS-CoV-2
por: Licinio, P., et al.
Publicado: (2022)

What are the key pediatric public policy priorities as the COVID-19 pandemic persists?
por: Schleiss, Mark R., et al.
Publicado: (2023)

Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia
por: Solis, Morgane, et al.
Publicado: (2022)

Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis
por: Alsaleh, Ghada, et al.
Publicado: (2010)

B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis
por: François, Antoine, et al.
Publicado: (2013)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries
por: El Kibbi, Lina, et al.
Publicado: (2022)

Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis
por: Petitdemange, Arthur, et al.
Publicado: (2020)

Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey
por: Petitdemange, Arthur, et al.
Publicado: (2021)

Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?
por: Chhibba, Tarun, et al.
Publicado: (2022)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies
por: Velay, Aurelie, et al.
Publicado: (2020)

Kinetics of cellular and humoral responses to third COVID-19 vaccine in heart transplant recipients: Correspondence
por: Sokaromdee, Pathum, et al.
Publicado: (2022)

Rituximab: Humoral immunodeficiency: case report
Publicado: (2021)

A call for immediate action to increase COVID-19 vaccination uptake to prepare for the third pandemic winter
por: Betsch, Cornelia, et al.
Publicado: (2022)

Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d2gvkl27mehlk74flf7fq6798c